Inflammatory factors and risk of meningiomas: a bidirectional mendelian-randomization study

Abstract

Background:

Meningiomas are one of the most common intracranial tumors, and the current understanding of meningioma pathology is still incomplete. Inflammatory factors play an important role in the pathophysiology of meningioma, but the causal relationship between inflammatory factors and meningioma is still unclear.

Method:

Mendelian randomization (MR) is an effective statistical method for reducing bias based on whole genome sequencing data. It’s a simple but powerful framework, that uses genetics to study aspects of human biology. Modern methods of MR make the process more robust by exploiting the many genetic variants that may exist for a given hypothesis. In this paper, MR is applied to understand the causal relationship between exposure and disease outcome.

Results:

This research presents a comprehensive MR study to study the association of genetic inflammatory cytokines with meningioma. Based on the results of our MR analysis, which examines 41 cytokines in the largest GWAS datasets available, we were able to draw the relatively more reliable conclusion that elevated levels of circulating TNF-β, CXCL1, and lower levels of IL-9 were suggestive associated with a higher risk of meningioma. Moreover, Meningiomas could cause lower levels of interleukin-16 and higher levels of CXCL10 in the blood.

Conclusion:

These findings suggest that TNF-β, CXCL1, and IL-9 play an important role in the development of meningiomas. Meningiomas also affect the expression of cytokines such as IL-16 and CXCL10. Further studies are needed to determine whether these biomarkers can be used to prevent or treat meningiomas.

Introduction

Meningiomas are brain tumors that occur in the meninges surrounding the brain and spinal cord (Brastianos et al., 2019). They are one of the most common primary intracranial tumors of the central nervous system (CNS) and are second only to glioma in incidence. The vast majority of meningiomas are benign and are classified as World Health Organization (WHO) grade I; those of WHO grade II are more aggressive; and a very small percentage are malignant (only 1 to 3%) and they belong to WHO grade III (Buerki et al., 2018). Benign meningiomas can be completely cured by surgery and radiotherapy, while malignant meningiomas have a higher frequency of local invasion, recurrence, and metastasis, and the treatment options are extremely limited (Maggio et al., 2021).

The majority of meningiomas are located outside the blood–brain barrier (BBB), rendering them more vulnerable to systemic immunology and inflammation compared to structures within the BBB (von Spreckelsen et al., 2022). A retrospective study revealed elevated levels of TNF-α in meningioma patients, which induces inflammatory damage, triggers inflammatory responses, and promotes the release of pro-inflammatory factors like IL-6 (Zheng et al., 2022). Earlier investigations have demonstrated that increased IL-10 within the tumor microenvironment, including meningiomas, is associated with a poorer prognosis (Singh et al., 2019; Manjunath et al., 2022), highlighting the crucial role of inflammatory factor regulation in the pathophysiology of meningioma. Cytokines have been identified as reliable screening targets for inflammation and pain in meningiomas, with potential diagnostic and therapeutic applications (Shamsdin et al., 2019). However, these studies have focused on a limited number of inflammatory factors and have not accounted for the influence of other physical factors on altered inflammatory factor levels. Hence, it is essential to ascertain whether changes in inflammatory factors contribute to tumorigenesis or if the tumor itself modifies the microenvironment, leading to variations in inflammatory factors. Given the incomplete understanding of the etiology of malignant meningiomas, investigating the precise nature of the interaction between inflammatory factors and meningiomas holds significant clinical importance.

To establish a causal relationship between exposure to inflammatory cytokines and the development of meningiomas, we can employ Mendelian randomization (MR). MR is an observational study design that leverages genetic variants as instrumental variables to estimate the causal effect of risk factors on health outcomes. Unlike traditional multivariable observational analyses, MR is less susceptible to confounding variables and measurement errors, and avoids bias arising from reverse causality. As a result, MR has become a reliable method to obtain robust estimates for the causal impact of various risk factors on health outcomes, often yielding results similar to those obtained from randomized controlled trials (RCTs) when available (Davey Smith and Hemani, 2014).

In our study, we conducted a bidirectional Mendelian randomization analysis using genetic variations as instrumental variables to assess the causal relationship between alterations in inflammatory cytokine levels and the risk of developing meningiomas (Bouras et al., 2022). We found no evidence of a link between genetically predicted inflammatory variables and levels of potential confounders. Thus, by assuming that the connection between genetic variants and meningiomas exclusively operates through exposure, Mendelian randomization analysis can be employed to ascertain the causal influence of inflammatory factors on the risk of developing meningiomas.

Methods

MR is based on three hypotheses: (1) the genetic instrumental variable (s) should be strongly associated with the exposure (risk factor of interest); (2) there should be no confounding variables that influence both the risk factor and the outcome, and these variables should not be associated with the genetic instrument associated with risk factor and outcome either; and (3) there should be no other pathways from the genetic instrument to the outcome other than through the risk factor of interest (Bowden and Holmes, 2019; Figure 1).

Figure 1

Summary statistics source

In this bidirectional Mendelian randomization study, the first step was to select appropriate genetic variants from publicly available genome-wide association study (GWAS) databases. SNPs were selected as IVs from GWAS databases for exposure and outcome. The SNPs associated with inflammatory factors were obtained from a study of 8,293 individuals that included 41 cytokines and growth factors (Ahola-Olli et al., 2017). Summary statistics for meningiomas were obtained from the UK Biobank, which included 307 cases and 456,041 controls of European ancestry, and a generalized linear mixed model (GLMM)-based method named (fastGWA-GLMM) was utilized with adjustments for covariates (Rusk, 2018). To prevent population stratification bias from confounding the findings, all SNPs and their accompanying pooled data were restricted to populations of European ancestry in this study (Jiang et al., 2021). Table 1 summarizes details about cytokines based on summary-level data from genome-wide association studies (GWAS).

Instrumental variables selection

We selected SNPs strongly associated with inflammatory factors, with genome-wide significance (P-value < 5 × 10^–8), as potential IVs (Burgess and Thompson, 2011). After that, we need to remove linkage disequilibrium (LD). Setting the threshold as r2 < 0.001, kb = 5,000, and removing the SNPs with r2 greater than 0.001 with the most significant SNP within 5,000 kb. Only 10 inflammatory cytokines had more than two independent SNPs at the P-value < 5 × 10^–8 level after reconciling the selected SNPs with the resulting data. Therefore, we widen the threshold to P-value < 5 × 10^–6 to select eligible instrumental variables. Through the above steps, we obtained 41 kinds of inflammatory factors. Due to the lowered significance threshold, IVs with F-statistics less than 10 were considered weak instrumental variables and would be excluded from our study. To comply with the law of Mendelian randomization, we will also screen the target SNPs to exclude SNPs associated with the results. Finally, the effect alleles of the genetic variants were coordinated in the exposure and outcome of GWAS, Supplementary Tables S1–S42.

Data analysis

In this study, we primarily used the inverse variance weighting (IVW) method to estimate the causal effect of exposure on the outcome, which required SNPs to fully comply with the three principles of MR studies to obtain correct causal estimates (Wang et al., 2022). And the method will provide the most accurate results when the selected SNPs are all valid IVs. We also applied several complementary methods, including the weighted median (WM) method, and MR Egger regression, to estimate the causal associations under different conditions (Bowden et al., 2016). The WM method uses the median MR estimate as the causal estimate and has some advantages over MR Egger regression because it provides lower type I error and higher causal estimation power. MR Egger uses the reciprocal of the resulting variances as the weights for the analysis. Different from IVW, MR Egger considers the presence of an intercept term in the regression analysis. The intercept of the MR Egger regression model reveals the presence or absence of horizontal pleiotropy (P-value < 0.05 is considered significant) (Burgess and Thompson, 2011). When horizontal pleiotropy is present, it indicates that IVs affect outcomes independently of exposure factors, which is inconsistent with the definition of IVs. Sensitivity analyses were also performed to ensure the stability of the findings, Table 2. The Cochran Q test was used to assess heterogeneity between SNPs, Table 2. When heterogeneity was present (P-value < 0.05), certain SNPs with small p-values needed to be excluded or a random-effects model was used directly to assess the MR effect. Finally, we performed the “leave-one-out” analysis to test the stability of the results, Supplementary Figures S1–S5. The packages ‘TwoSampleMR’ in R version 4.2.2 were used for the analysis.

Results

Genetically predicted systemic inflammatory regulators are associated with meningiomas, as evidenced by the following results. The higher tumor necrosis factor-beta (TNF-β) (OR = 1.351, 95% CI = 1.015–1.797) and CXCL1 (Growth regulated oncogene-α) (OR = 1.291, 95% CI = 1.002–1.663) levels are associated with an increased risk of meningiomas using IVW methods, Table 3. MR-Egger Intercept did not detect potential horizontal pleiotropy (P-value > 0.05). Furthermore, MR-Egger and IVW heterogeneity tests showed that there was no obvious heterogeneity (P-value > 0.05). Leave-one-out studies were used for sensitivity analysis and demonstrated no influence, Supplementary Figures S1, S3. Moreover, we found that higher interleukin-9 (IL-9) levels can reduce meningioma risk (OR = 0.544, 95% CI = 0.322–0.918) using IVW methods. There was no heterogeneity or horizontal pleiotropy in the results (P-value > 0.05). The above results are listed in Tables 2, 3.

Similarly, we found an association between genetically predicted meningiomas and cytokine levels. Genetically predicted meningiomas were associated with levels of interleukin-16 (IL-16) (BETA = −0.037, 95% CI = −0.069 ~ −0.004) and interferon gamma-induced protein 10 (IP10) (BETA = 0.036, 95% CI = 0.003–0.068) using IVW methods. There was no evidence of pleiotropy and heterogeneity observed in these results. The above results are summarized in Tables 2, 3. The Figures of Leave-one-out Analysis, Scatter Plot, Funnel Plot, and Forest Plot are listed in Supplementary material.

Discussion

Meningiomas are one of the most common intracranial tumors. Most meningiomas occur intracranially, and a small proportion occurs in the spinal cord. Meningiomas usually grow gradually, with many tumors appearing in inaccessible places (Buerki et al., 2018; Hou et al., 2021). This sporadic behavior creates a therapeutic challenge for clinicians, as it makes it difficult to achieve complete and complete tumor removal, which in turn often leads to postoperative recurrences (Maggio et al., 2021). Inflammation in meningioma is an important part of the pathogenesis and progression. Studies have shown that in response to various stimuli and signals, circulating (systemic) immune cells can migrate out of the cerebral vasculature and into the perivascular space and brain parenchyma (Domingues et al., 2016). Most meningiomas occur outside the blood–brain barrier (BBB) and can be infiltrated by different cell types, mainly immune cells, making them more susceptible to systemic immunity and inflammation than structures inside the BBB. Some meningioma variants have also been shown to be associated with systemic inflammatory syndromes (Polyzoidis et al., 2015). Other studies have shown that the proportion of immune cells changes significantly during the development of meningiomas, suggesting that meningiomas also affect the immune response process (Sahab-Negah and Gorji, 2020). However, reverse causality and residual confounding are common biases in these traditional observational studies. Whether these changes in inflammatory modulators cause meningiomas or are a response to meningiomas remains to be investigated. Therefore, there is an urgent need for a more comprehensive understanding of the pathogenesis of meningioma, which could lead to greater advances in therapeutic approaches.

Meanwhile, by using genetic variation as an instrumental variable that can alter exposure to instrumental variables, MR studies can overcome the limitations of observational studies by examining the independent conventional biases associated with observational studies (Davey Smith and Hemani, 2014). This research presents a comprehensive MR study to study the association of genetic inflammatory cytokines with meningioma. Based on the results of our MR analysis, which examines 41 cytokines in the largest GWAS datasets available, we were able to draw the relatively more reliable conclusion that elevated levels of circulating TNF-β, CXCL1, and lower levels of IL-9 were associated with a high risk of meningioma.

TNF-β is involved in regulating tumor cell proliferation, invasion, and apoptosis, and influencing the formation of the tumor microenvironment. TNF-β activates multiple signaling pathways, including NF-κB and MAPK, promoting inflammatory responses and cell survival. Additionally, TNF-beta can induce angiogenesis, providing nutrients and oxygen to the tumor (Buhrmann et al., 2019; Zhong et al., 2022). However, there is a lack of definitive research evidence regarding the association between TNF-beta and the prognosis of meningioma patients. Some studies have shown higher levels of TNF-beta in the peripheral blood of meningioma patients compared to normal individuals (Boyle-Walsh et al., 1996), which may be associated with increased tumor invasiveness, higher risk of recurrence, and enhanced resistance to treatment. Increased expression of CXCL1 is associated with tumor development and progression in meningiomas. CXCL1 is a chemokine that attracts leukocytes and other immune cells to sites of inflammation or tumors (Acharyya et al., 2012). Research has demonstrated that CXCL1 can promote the proliferation of human meningioma cells (Barbieri et al., 2006). In our study, using a Mendelian randomization approach, we also found that elevated levels of CXCL1 are associated with an increased risk of developing meningiomas. This finding supports the role of CXCL1 in meningioma pathogenesis and suggests its potential as a risk factor for the development of this tumor. The ability of CXCL1 to enhance cell proliferation provides a mechanistic explanation for its involvement in meningioma development. These findings highlight the importance of CXCL1 as a potential therapeutic target and underscore the need for further investigations to explore its precise mechanisms of action in meningioma tumorigenesis. IL-9 activates downstream signaling pathways, such as JAK/STAT and MAPK, by binding to its receptor IL-9R. In certain tumor types, IL-9 may promote tumor growth and metastasis (Angkasekwinai and Dong, 2021). In contrast, our study found that elevated levels of IL-9 in peripheral blood are associated with a decreased risk of developing meningiomas. However, the specific mechanisms of IL-9 in meningiomas require further investigation. Overall, TNF-beta may promote tumor growth and metastasis in meningiomas, while CXCL1 may be involved in tumor invasiveness and resistance to treatment. The role of IL-9 in meningiomas requires further investigation. These research findings provide an important foundation for gaining a deeper understanding of the mechanisms underlying meningioma development and for developing corresponding therapeutic strategies.

The bilateral MR analysis in this study also showed that meningiomas may not be correlated with changes in blood cytokine levels. IL-16, as a multifunctional cytokine, plays a role in regulating immune cell functions in cancer. It enhances the activity of natural killer (NK) cells and promotes cytotoxicity of T cells, thereby inhibiting tumor cell proliferation and dissemination. Additionally, IL-16 has been associated with poor prognosis in cancers such as gastric cancer, possibly due to its ability to attract other immune cells into the tumor microenvironment, including regulatory T cells, influencing tumor growth and progression (Liu et al., 2016; Xiong et al., 2022). Our research findings indicate that meningiomas lead to a decrease in IL-16 levels, although the evidence regarding the relationship between meningiomas and IL-16 is limited. We speculate that the decrease in IL-16 levels may suggest the presence of similar immunosuppressive mechanisms in the meningioma microenvironment, which contribute to tumor growth and evasion of immune surveillance. On the other hand, IP-10 (also known as CXCL10) is a chemokine involved in recruiting and activating immune cells. Elevated levels of IP-10 have been observed in various cancers and are associated with tumor progression, angiogenesis, and immune cell infiltration (Karin and Razon, 2018; Chen et al., 2020; Wu et al., 2021; Limagne et al., 2022). The increased levels of IP-10 in the blood of meningioma patients may reflect inflammatory responses to the tumor or aggregation of immune cells. In summary, the alterations in IL-16 and IP-10 levels in the blood of meningioma patients indicate complex interactions between tumors and the immune system. These findings support the importance of cytokine dysregulation and immune modulation in the pathogenesis of meningiomas. Further research is needed to elucidate the precise mechanisms underlying these cytokine changes and their impact on the development, progression, and therapeutic strategies for meningiomas.

There are several limitations to our study. Firstly, in the GWAS data for cytokines, we used a significance cut-off of P-value < 5 × 10⁻⁶ because only 10 had at least one genome-wide significant SNP at a cut-off of P-value < 5 × 10⁻⁸. Secondly, the result of our MR-Egger and Weight Median estimates were not significant. As the statistical power of the IVW method was significantly higher than other MR methods, especially MR-Egger, and the fact that we followed the strengthened requirement in the consistent β-direction of MR methods in our study, our result can also be considered significant. The third issue is that all GWAS data are from European populations and there is a shortcoming of whether our findings will be consistent across populations, which remains to be seen. The results of these studies may be influenced by other measured and unmeasured confounders, and cytokine production may be influenced by many other factors, including the cytokine network system, rather than the disease itself.

Funding

This work was supported by the Natural Science Foundation of Jilin Province to Xing Su (YDZJ202301ZYTS081).

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

• 1

  Acharyya S. Oskarsson T. Vanharanta S. Malladi S. Kim J. Morris P. G. et al . (2012). A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cells150, 165–178. doi: 10.1016/j.cell.2012.04.042

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2

  Ahola-Olli A. V. Würtz P. Havulinna A. S. Aalto K. Pitkänen N. Lehtimäki T. et al . (2017). Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors. Am. J. Hum. Genet.100, 40–50. doi: 10.1016/j.ajhg.2016.11.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 3

  Angkasekwinai P. Dong C. (2021). IL-9-producing T cells: potential players in allergy and cancer. Nat. Rev. Immunol.21, 37–48. doi: 10.1038/s41577-020-0396-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4

  Barbieri F. Bajetto A. Porcile C. Pattarozzi A. Massa A. Lunardi G. et al . (2006). CXC receptor and chemokine expression in human meningioma: SDF1/CXCR4 signaling activates ERK1/2 and stimulates meningioma cell proliferation. Ann. N. Y. Acad. Sci.1090, 332–343. doi: 10.1196/annals.1378.037

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5

  Bouras E. Karhunen V. Gill D. Huang J. Haycock P. C. Gunter M. J. et al . (2022). Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis. BMC Med.20:3. doi: 10.1186/s12916-021-02193-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6

  Bowden J. Davey Smith G. Haycock P. C. Burgess S. (2016). Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet. Epidemiol.40, 304–314. doi: 10.1002/gepi.21965

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7

  Bowden J. Holmes M. V. (2019). Meta-analysis and Mendelian randomization: a review. Res. Synth. Methods10, 486–496. doi: 10.1002/jrsm.1346

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8

  Boyle-Walsh E. Birch M. Gallagher J. A. Speirs V. White M. C. Shenkin A. et al . (1996). RT-PCR detection of cytokine transcripts in a series of cultured human meningiomas. J. Pathol.178, 442–446. doi: 10.1002/(SICI)1096-9896(199604)178:4<442::AID-PATH521>3.0.CO;2-I

  • CrossRef
  • Google Scholar

• 9

  Brastianos P. K. Galanis E. Butowski N. Chan J. W. Dunn I. F. Goldbrunner R. et al . (2019). Advances in multidisciplinary therapy for meningiomas. Neurooncology21, i18–i31. doi: 10.1093/neuonc/noy136

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10

  Buerki R. A. Horbinski C. M. Kruser T. Horowitz P. M. James C. D. Lukas R. V. (2018). An overview of meningiomas. Fut. Oncol.14, 2161–2177. doi: 10.2217/fon-2018-0006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11

  Buhrmann C. Yazdi M. Popper B. Shayan P. Goel A. Aggarwal B. B. et al . (2019). Evidence that TNF-β induces proliferation in colorectal cancer cells and resveratrol can down-modulate it. Exp. Biol. Med.244, 1–12. doi: 10.1177/1535370218824538

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12

  Burgess S. Thompson S. G. (2011). CRP CHD genetics collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. Int. J. Epidemiol.40, 755–764. doi: 10.1093/ije/dyr036

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13

  Chen J. Chen Q.-L. Wang W.-H. Chen X.-L. Hu X.-Q. Liang Z.-Q. et al . (2020). Prognostic and predictive values of CXCL10 in colorectal cancer. Clin. Transl. Oncol.22, 1548–1564. doi: 10.1007/s12094-020-02299-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14

  Davey Smith G. Hemani G. (2014). Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum. Mol. Genet.23, R89–R98. doi: 10.1093/hmg/ddu328

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15

  Domingues P. González-Tablas M. Otero Á. Pascual D. Miranda D. Ruiz L. et al . (2016). Tumor infiltrating immune cells in gliomas and meningiomas. Brain Behav. Immun.53, 1–15. doi: 10.1016/j.bbi.2015.07.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16

  Hou Y. Xie H. Dou G. Yang W. Ge J. Zhou B. et al . (2021). Computational study on novel natural inhibitors targeting c-MET. Medicine100:e27171. doi: 10.1097/MD.0000000000027171

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17

  Jiang L. Zheng Z. Fang H. Yang J. (2021). A generalized linear mixed model association tool for biobank-scale data. Nat. Genet.53, 1616–1621. doi: 10.1038/s41588-021-00954-4

  • CrossRef
  • Google Scholar

• 18

  Karin N. Razon H. (2018). Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. Cytokine109, 24–28. doi: 10.1016/j.cyto.2018.02.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19

  Limagne E. Nuttin L. Thibaudin M. Jacquin E. Aucagne R. Bon M. et al . (2022). MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. Cancer Cell40, 136–152.e12. doi: 10.1016/j.ccell.2021.12.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 20

  Liu F.-T. Zhu P.-Q. Ou Y.-X. Liu W.-W. Xia G.-F. Luo H.-L. (2016). Positive association between IL-16 rs1131445 polymorphism and cancer risk: a meta-analysis. Minerva Med.107, 84–91. PMID:

  • Pubmed Abstract
  • Google Scholar

• 21

  Maggio I. Franceschi E. Tosoni A. Nunno V. D. Gatto L. Lodi R. et al . (2021). Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. CNS. Oncologia10:CNS72. doi: 10.2217/cns-2021-0003

  • CrossRef
  • Google Scholar

• 22

  Manjunath N. Mishra S. Garg K. Suri V. Sharma M. C. Tandon V. et al . (2022). Is there any relationship between systemic inflammatory markers and meningioma grade?Neurol. India70, 223–230. doi: 10.4103/0028-3886.338647

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23

  Polyzoidis S. Koletsa T. Panagiotidou S. Ashkan K. Theoharides T. C. (2015). Mast cells in meningiomas and brain inflammation. J. Neuroinflammation12:170. doi: 10.1186/s12974-015-0388-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24

  Rusk N. (2018). The UK biobank. Nat. Methods15:1001. doi: 10.1038/s41592-018-0245-2

  • CrossRef
  • Google Scholar

• 25

  Sahab-Negah S. Gorji A. (2020). Meningioma tumor microenvironment. Adv. Exp. Med. Biol.1296, 33–48. doi: 10.1007/978-3-030-59038-3_3

  • CrossRef
  • Google Scholar

• 26

  Shamsdin S. A. Mehrafshan A. Rakei S. M. Mehrabani D. (2019). Evaluation of VEGF, FGF and PDGF and serum levels of inflammatory cytokines in patients with glioma and meningioma in southern Iran. Asian Pac. J. Cancer Prev.20, 2883–2890. doi: 10.31557/APJCP.2019.20.10.2883

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27

  Singh N. Baby D. Rajguru J. P. Patil P. B. Thakkannavar S. S. Pujari V. B. (2019). Inflammation and cancer. Ann. Afr. Med.18, 121–126. doi: 10.4103/aam.aam_56_18

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28

  von Spreckelsen N. Kesseler C. Brokinkel B. Goldbrunner R. Perry A. Mawrin C. (2022). Molecular neuropathology of brain-invasive meningiomas. Brain Pathol.32:e13048. doi: 10.1111/bpa.13048

  • CrossRef
  • Google Scholar

• 29

  Wang J. Liu D. Tian E. Guo Z.-Q. Chen J.-Y. Kong W.-J. et al . (2022). Is hearing impairment causally associated with falls? Evidence from a two-sample Mendelian randomization study. Front. Neurol.13:876165. doi: 10.3389/fneur.2022.876165

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30

  Wu B. Zhang Z. Dou G. Lv X. Ge J. Wang H. et al . (2021). Novel natural inhibitors targeting B-RAF(V600E) by computational study. Bioengineered12, 2970–2983. doi: 10.1080/21655979.2021.1943113

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31

  Xiong J. Hu H. Kang W. Shao X. Li Y. Jin P. et al . (2022). Association of sarcopenia and expression of interleukin-16 in gastric cancer survival. Nutrients14:14. doi: 10.3390/nu14040838

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32

  Zheng Z. Jia L. Zhang P. Tian Y. Chen X. (2022). Effectiveness of super-selective embolization for parasagittal meningiomas and its effect on the level of inflammatory factors. Evid. Based Complement. Alternat. Med.2022, 1–6. doi: 10.1155/2022/2466007

  • CrossRef
  • Google Scholar

• 33

  Zhong S. Zhang Z. Guo Z. Yang W. Dou G. Lv X. et al . (2022). Identification of novel natural inhibitors targeting AKT serine/threonine kinase 1 (AKT1) by computational study. Bioengineered13, 12003–12020. doi: 10.1080/21655979.2021.2011631

  • Pubmed Abstract
  • CrossRef
  • Google Scholar